Sinus augmentation using human mesenchymal stem cells loaded into a β-tricalcium phosphate/hydroxyapatite scaffold

被引:127
|
作者
Shayesteh, Yadollah Soleymani [2 ]
Khojasteh, Arash [3 ]
Soleimani, Masoud [1 ]
Alikhasi, Marzieh
Khoshzaban, Ahad [4 ]
Ahmadbeigi, Naser [5 ]
机构
[1] Tarbiat Modares Univ, Sch Med Sci, Dept Hematol, Tehran, Iran
[2] Univ Tehran Med Sci, Fac Dent, Tehran, Iran
[3] Shahid Beheshti Univ Med Sci, Taleghani Hosp, Tehran, Iran
[4] Univ Tehran Med Sci, Imam Khomeini Hosp, Iranian Tissue Bank Res & Preparat Ctr, Tehran, Iran
[5] Stem Cell Technol Ctr, Stem Cell Dept, Tehran, Iran
关键词
D O I
10.1016/j.tripleo.2007.12.001
中图分类号
R78 [口腔科学];
学科分类号
1003 ;
摘要
Objective. Implant placement in the posterior maxilla may often be contraindicated because of insufficient bone volume and presence of the maxillary sinus. In these situations, sinus floor augmentation frequently has been proposed as the best treatment. This clinical study was based on the hypothesis that the clinical effectiveness of adult mesenchymal stem cells (MSCs) loaded to the biphasic scaffold. Methods. In this report, the clinical and radiographic results are presented on 6 consecutively treated patients using MSCs in combination with biphasic hydroxyl apatite/beta-tricalcium phosphate (HA/TCP) for sinus elevation. All the patients in the study had less than 3 mm initial bone height in the posterior maxillary area (IBH). MSCs were cultured and expanded from bone marrow aspirate for each patient. Three months after sinus elevation, radiographic evaluation was performed for the patients and the secondary bone height was measured (SBH1). In the second stage surgery, 30 implants were placed. Trephine bur was used as a pilot drill and a core biopsy was obtained from each implant site. Prosthetic rehabilitation of the patients was performed after 4 months. Secondary bone height was measured 9 months after implant placement (SBH2). Results. Of 30 implants, 28 (93%) were considered clinically successful. Two implants were removed due to mobility at the time of surgical exposure. Histologic evaluation of the biopsy specimens revealed numerous areas of osteoid and bone formation HA/TCP, with no evidence of inflammatory cell infiltrate. Mean bone regenerate was 41.34%. Clinically, no complications were observed, and all implants were considered clinically osseointegrated after 4 months. Mean bone height was measured 3 and 12 months after sinus grafting (mean of SBH1 = 12.08 mm and mean of SBH2 = 10.08 mm). Conclusions. These clinical and histological findings suggest that sinus grafting with HA/TCP in combination with MSCs provide a viable therapeutic alternative for implant placement. The findings suggest that the addition of MSCs to bone derivative/substitute materials may enhance bone formation in the maxillary sinus area. Of course more studies with the control groups are needed for the evaluation of this method as a clinical solution for the patients.
引用
收藏
页码:203 / 209
页数:7
相关论文
共 50 条
  • [41] Utilizing Autologous Multipotent Mesenchymal Stromal Cells and β-Tricalcium Phosphate Scaffold in Human Bone Defects: A Prospective, Controlled Feasibility Trial
    Sponer, Pavel
    Filip, Stanislav
    Kucera, Tomas
    Brtkova, Jindra
    Urban, Karel
    Palicka, Vladimir
    Koci, Zuzana
    Syka, Michael
    Bezrouk, Ales
    Sykova, Eva
    BIOMED RESEARCH INTERNATIONAL, 2016, 2016
  • [42] Applications of Mesenchymal Stem Cells in Sinus Lift Augmentation as a Dental Implant Technology
    Parnia, Feridoun
    Yazdani, Javad
    Dizaj, Solmaz Maleki
    STEM CELLS INTERNATIONAL, 2018, 2018
  • [43] Indirect fabrication of hydroxyapatite/β-tricalcium phosphate scaffold for osseous tissue formation using additive manufacturing technology
    Sapkal, Pranav S.
    Kuthe, Abhaykumar M.
    Kashyap, Rajpal S.
    Nayak, Amit R.
    Kuthe, Sudhanshu A.
    Kawle, Anuja P.
    JOURNAL OF POROUS MATERIALS, 2016, 23 (06) : 1567 - 1574
  • [44] Indirect fabrication of hydroxyapatite/β-tricalcium phosphate scaffold for osseous tissue formation using additive manufacturing technology
    Pranav S. Sapkal
    Abhaykumar M. Kuthe
    Rajpal S. Kashyap
    Amit R. Nayak
    Sudhanshu A. Kuthe
    Anuja P. Kawle
    Journal of Porous Materials, 2016, 23 : 1567 - 1574
  • [45] Histomorphometric and immunohistochemical analysis of human maxillary sinus-floor augmentation using porous -tricalcium phosphate for dental implant treatment
    Miyamoto, Shinji
    Shinmyouzu, Kouhei
    Miyamoto, Ikuya
    Takeshita, Kenji
    Terada, Toshihisa
    Takahashi, Tetsu
    CLINICAL ORAL IMPLANTS RESEARCH, 2013, 24 : 134 - 138
  • [46] Microstructured scaffold coated with hydroxyapatite/collagen nanocomposite multilayer for enhanced osteogenic induction of human mesenchymal stem cells
    Kim, Taek Gyoung
    Park, Suk-Hee
    Chung, Hyun Jung
    Yang, Dong-Yol
    Park, Tae Gwan
    JOURNAL OF MATERIALS CHEMISTRY, 2010, 20 (40) : 8927 - 8933
  • [47] Ectopic Osteogenesis of Allogeneic Bone Mesenchymal Stem Cells Loading on β-Tricalcium Phosphate in Canines
    Xie, Fang
    Teng, Li
    Wang, Qian
    Sun, Xue-Jian
    Cai, Lei
    Zeng, Hai-Feng
    Xiao, Ran
    PLASTIC AND RECONSTRUCTIVE SURGERY, 2014, 133 (02) : 142E - 153E
  • [48] Osteogenic differentiation of mesenchymal stem cells in biodegradable sponges composed of gelatin and β-tricalcium phosphate
    Takahashi, Y
    Yamamoto, M
    Tabata, Y
    BIOMATERIALS, 2005, 26 (17) : 3587 - 3596
  • [49] The effect of synthetic α-tricalcium phosphate on osteogenic differentiation of rat bone mesenchymal stem cells
    Liu, Jinzhong
    Zhao, Liang
    Ni, Ling
    Qiao, Chunyan
    Li, Daowei
    Sun, Hongchen
    Zhang, Zongtao
    AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2015, 7 (09): : 1588 - 1601
  • [50] Cartilage tissue regeneration using kartogenin loaded hybrid scaffold for the chondrogenic of adipose mesenchymal stem cells
    Sepahdar, Asma
    Nazbar, Abolfazl
    Bahadorikhalili, Saeed
    Rezaei, Ghassem
    Shokrgozar, Mohammad Ali
    Dehghan, Mohammad Mehdi
    Javar, Hamid Akbari
    Bonakdar, Shahin
    JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY, 2022, 73